Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T-cell Acute Lymphoblastic Leukemia clinical trials
7 of 7 indexed T-cell Acute Lymphoblastic Leukemia trials are currently recruiting.
7 US clinical trials · 7 currently recruiting
T-cell Acute Lymphoblastic Leukemia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 2 of these trials.
The research picture
T-cell Acute Lymphoblastic Leukemia has 7 registered US clinical trials, 7 of them open to new participants right now, about 100% of the total.
- 7
- recruiting participants now
- 100%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Baylor College of Medicine
Active & Recent Trials
7 total, page 1 of 1
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen
NCT06514794
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06390319
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Baylor College of Medicine
NCT03081910
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
New York Medical College
NCT04972942
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Baylor College of Medicine
NCT03690011
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
NCT06561074
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
NCT05289687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the T-cell Acute Lymphoblastic Leukemia Trial Landscape
7 indexed T-cell Acute Lymphoblastic Leukemia studies · 7 recruiting (100%).
Phase mix: 0 late (III/IV) vs 7 early (I/II).
Top sponsor: Baylor College of Medicine (2 trials), 5 others listed. 7 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for T-cell Acute Lymphoblastic Leukemia?
PlainTrial tracks 7 US clinical trials for T-cell Acute Lymphoblastic Leukemia, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for T-cell Acute Lymphoblastic Leukemia?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.